Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients

HIV Medicine

Volumn 14, Issue 7, 2013, Pages 449-452

  Jansen, A ^a   Colbers, Eph ^b   van der Ven, Ajam ^b   Richter, C ^a   Rockstroh, Jk ^c   Wasmuth, Jc ^c   van Luin, M ^a   Burger, Dm ^b  

^a Alysis Zorggroep   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Antiretroviral agents; Atazanavir; Drug interactions; HIV integrase inhibitor; Pharmacokinetics; Raltegravir

Indexed keywords

ATAZANAVIR; EMTRICITABINE; LAMIVUDINE; RALTEGRAVIR;

ADULT; AGED; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTIRETROVIRAL AGENTS; ATAZANAVIR; DRUG INTERACTIONS; HIV INTEGRASE INHIBITOR; PHARMACOKINETICS; RALTEGRAVIR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; YOUNG ADULT;

EID: 84879841420     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12029     Document Type: Article

References (10)

1. Thompson MA, Aberg JA, Hoy JF etal. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387-402.
2. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. ClinPharmacokinet 2005; 44: 1035-1050.
3. Steigbigel RT, Cooper DA, Teppler H etal. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials. ClinInfectDis. 2010; 50: 605-612.
4. Iwamoto M, Wenning LA, Mistry GC etal. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. ClinInfectDis. 2008; 47: 137-140.
5. Zhu L, Butterton J, Persson A etal. Pharmacokinetics and safety of twice-daily atazanavir 300mg and raltegravir 400mg in healthy individuals. AntivirTher. 2010; 15: 1107-1114.
6. Rizk ML, Hang Y, Luo WL etal. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012; 56: 3101-3106.
7. Eron JJ, Jr, Rockstroh JK, Reynes J etal. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11: 907-915.
8. Cordery DV, Hesse K, Amin J, Cooper DA. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antiviral Therapy. 2010; 15: 1035-1038.
9. Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit 2010; 32: 782-786.
10. Kozal MJ, Lupo S, DeJesus E etal. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clinical Trials. 2012; 13: 119-130.